Kymera Therapeutics To Present New Preclinical Data For KT-621, An Oral STAT6 Degrader At The ATS Annual Meeting; KT-621 Expected To Start Phase 1 In The Second Half Of 2024, With Phase 1 Data In The First Half Of 2025
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics announced new preclinical data for KT-621, an oral STAT6 degrader, at the ATS Annual Meeting. KT-621 showed comparable or superior activity to dupilumab in preclinical asthma models. Phase 1 trials are expected to start in the second half of 2024, with data available in the first half of 2025.
May 22, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics presented promising preclinical data for KT-621, an oral STAT6 degrader, showing comparable or superior activity to dupilumab in asthma models. Phase 1 trials are expected to start in the second half of 2024, with data available in the first half of 2025.
The presentation of promising preclinical data for KT-621, showing comparable or superior activity to dupilumab, is likely to positively impact Kymera Therapeutics' stock. The initiation of Phase 1 trials in the second half of 2024 and the expected data in the first half of 2025 provide a clear timeline for investors, potentially boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100